Immunohistochemistry PD-L1 scoring in NSCLC (TPS)

Provide PD-L1 expression predictive biomarker scoring proficiency testing to individual pathologists, trainees and laboratories applying a Tumour Proportion Score (TPS) in NSCLC for pembrolizumab (Keytruda). Participants can assess their scoring skills and compare performance with that of their peers and selected scoring experts, with the purpose of performance improvement.

For laboratory technical proficiency testing, please refer to program “Immunohistochemistry PD-L1 for NSCLC”.